Press Releases

 

Specialised Therapeutics to Remove Territory Sales Incentives from Staff Bonus Plan

February 1, 2017: In-field representatives will no longer receive incentive payments based on prescription volumes. STA introducing model to improve transparency, relationships with healthcare professionals.

Specialised Therapeutics to Relaunch GELCLAIR in Australia

April 4, 2017: Independent pharmaceutical company Specialised Therapeutics Asia (ST Asia) will today relaunch a product used to relieve the pain of oral mucositis, a condition that can affect cancer patients undergoing chemotherapy and/or radiotherapy.

Study Finds ABRAXANE Combination Chemotherapy is Superior to Other Chemotherapy Combinations in Women with Metastatic Triple Negative Breast Cancer

December 23, 2016: An international study has found that women with metastatic triple-negative breast cancer (mTNBC) demonstrated improved progression-free survival when treated with a combination of ABRAXANE (nanoparticle albumin-bound paclitaxel) and carboplatin, compared to other chemotherapy combinations.

Aeterna Zentaris and Specialised Therapeutics Asia Sign Exclusive License Agreement for the Potential Marketing of Zoptrex™ in Australia and New Zealand

October 12, 2016: Aeterna Zentaris Inc. and STA today announced the signing of an exclusive license agreement for the Company’s lead investigational anti-cancer compound, Zoptrex™ (zoptarelin doxorubicin), for the territories of Australia and New Zealand.

Specialised Therapeutics Strikes Deal With World Courier Australia To Manage Logistics For Specialty Pharma Products

June 16, 2016: International biopharmaceutical company Specialised Therapeutics Australia has struck an important agreement with global logistics partner World Courier Australia (WCA) to manage and handle its growing portfolio of specialist healthcare products around the country.

Specialized Therapeutics Grants Sublicense for Anti-Emetic Products to Mundipharma for Australia and New Zealand

March, 2016: Specialized Therapeutics Pty Ltd and Mundipharma Pty Limited today announce a sublicense agreement enabling Mundipharma to assume all commercialisation responsibilities for the anti-emetic products ALOXI® (palonosetron hydrochloride) and AKYNZEO® (netupitant/palonesetron).

Novel Multiple Myeloma Drug APLIDIN® Shows Positive Results in Pivotal Phase 3 Study

March 31, 2016: International biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST Asia) will seek regulatory approvals for novel multiple myeloma drug Aplidin® (plitidepsin) following the release of positive results in a pivotal Phase 3 study.

Specialised Therapeutics Asia To Distribute Novel Multiple Myeloma Drug APLIDIN® in South East Asia, Australia And New Zealand

February 2, 2016: International biopharmaceutical company Specialised Therapeutics Asia (ST Asia) will supply and distribute a novel oncology drug candidate throughout South East Asia, following an exclusive licensing deal with European pharmaceutical company PharmaMar.

TAILORx trial finds 99 percent of women with low Oncotype DX® Recurrence Score® results are free of breast cancer recurrence after five years of hormone therapy alone

September 29, 2015: Specialised Therapeutics Australia and Genomic Health announce the presentation of the first results1 from the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx, a large, prospectively conducted trial, designed and conducted by the ECOG-ACRIN Cancer Research Group under the sponsorship of the U.S. National Cancer Institute (NCI).

Specialised Therapeutics’ Breakthrough Brain Tumour Visualisation Drug GLIOLAN® Approved For Use in New Zealand

September 17, 2015: A NOVEL drug which helps neurosurgeons to better visualise and remove malignant brain tumours has been approved for marketing and distribution in New Zealand by Medsafe.

Cutting Edge Breast Cancer Test ‘Should Be Reimbursed’ – Medical Experts

September 3, 2015: A BREAKTHROUGH genetic test that could spare thousands of Australian women with early stage breast cancer from chemotherapy and its toxic side effects will be considered for reimbursement later this year.

STA: License Agreement with PharmaMar to Market, Distribute Oncology Drug APLIDIN® (plitidepsin) in AU and NZ

August 20, 2015: Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN® (plitidepsin) in Australia and New Zealand.

TGA Approves AKYNZEO® (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)

May 8, 2015: Australian biopharmaceutical company Specialised Therapeutics Australia (STA) and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration (TGA) has approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.1

Ariad and STA announce approval of ICLUSIG™ (ponatinib) in Australia

November 24, 2014: ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), today announced the marketing approval of ICLUSIG™ (ponatinib) in Australia by the Therapeutic Goods Administration (TGA).

STA Announces Breakthrough Cancer Drug ABRAXANE® to be PBS Listed for Metastatic Pancreatic Cancer

October 31, 2014: Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce ABRAXANE®(nanoparticle albumin-bound paclitaxel) in combination with gemcitabine, will be reimbursed via the Pharmaceutical Benefits Scheme (PBS) for patients with metastatic pancreatic cancer from the 1st of November.

STA to License New Drug – ILUVIEN® – to Improve Vision in Patients with Diabetes-Induced Vision Loss

April 28, 2014: Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia (STA) and Alimera Sciences. (NASDAQ: ALIM).

STA Receives TGA Approval for ABRAXANE® in Combination with Gemcitabine for First-Line Treatment of Metastatic Pancreatic Cancer

March, 2014: Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in now approved by the Therapeutic Goods Administration (TGA) for the first-line treatment of metastatic pancreatic cancer.

Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients

January 7, 2014: Australian women will potentially have greater access to the only genomic test validated to predict whether patients with early-stage invasive breast cancer would benefit from chemotherapy, following an agreement between Specialised Therapeutics Australia (STA) and Genomic Health, Inc. (NASDAQ: GHDX).

ARIAD Announces Commercial Agreement for ICLUSIG® (ponatinib) in Australia

January 28, 2014: ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), a specialty pharmaceutical company, today announced that ARIAD has granted STA exclusive rights to commercialize Iclusig® (ponatinib) in Australia in patients with Philadelphia-positive (Ph+) leukemias.

Specialised Therapeutics Australia Receives Therapeutic Goods Administration Approval for Brain Tumour Visualisation Drug - GLIOLAN®

November, 2013: A novel drug which assists neurosurgeons to better visualise and remove malignant brain tumours has been approved by the Therapeutic Goods Administration (TGA).

New ‘Superbug’ Antibiotic Approved For Use In Australia

April 26, 2013: An effective new antibiotic designed to specifically treat the common superbug* infection Clostridium difficile-associated diarrhoea will be available to patients in Australia from 14th May 2013.

ABRAXANE® plus Gemcitabine Improves Survival in Phase III Study of Patients with Advanced Pancreatic Cancer

January 23, 2013: Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.1

ABRAXANE® Demonstrates Significant Improvement in Progression-free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients

October 25, 2012: Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.1

Helsinn Grants Specialised Therapeutics Australia (STA) Rights to Anamorelin, a First-in-Class Compound to Treat Cachexia-Anorexia Related to Non-Small Cell Lung Cancer (NSCLC)

October 15, 2012: Melbourne biopharmaceutical company Specialised Therapeutics Australia (STA) has been granted exclusive commercialisation rights to a new drug for the treatment of NSCLC cachexia-anorexia.

GLIOLAN® Granted Orphan Drug Status by the Therapeutic Goods Administration

April, 2012: A drug which aids neurosurgeons to better visualise and more completely remove malignant brain tumours has been granted orphan drug status by the Therapeutic Goods Administration (TGA).

Specialised Therapeutics Australia Extends Collaboration with Swiss Helsinn Group

August 10, 2011: Melbourne bio-pharmaceutical company Specialised Therapeutics Australia plans to further expand its oncology portfolio, to include a new product for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Specialised Therapeutics to License Brain Tumour Visualisation Drug GLIOLAN® in Australia & NZ

June, 2011: A new drug which aids neurosurgeons to better visualise and operate on high grade glioma, a type of brain tumour which has a poor prognosis, has been in-licensed by Melbourne bio-pharmaceutical company Specialised Therapeutics Australia Pty Ltd (STA).

World Leading Breast Cancer Drug Now Available in New Zealand

February 21, 2011: New Zealand women now have access to a leading breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.

Specialised Therapeutics and Helsinn Group Announce a PBS Listing For ALOXI® (Palonosetron) in Australia

November 1, 2010: A world leading anti-nausea/anti-vomiting drug for cancer patients undergoing chemotherapy will be available in Australia on the Pharmaceutical Benefits Scheme (PBS) from November 1st 2010.

Celgene acquires Abraxis BioScience and leading anti-cancer drug Abraxane

October 20, 2010: Celgene Corporation (NASDAQ: CELG) today announced it has completed its acquisition of Abraxis BioScience, Inc. The transaction adds Abraxane®(nanoparticle albumin-bound paclitaxel) to the company’s existing portfolio of leading cancer products and offers another significant scientific platform that may drive future development.

Study Shows Leading Breast Cancer Drug ABRAXANE® Increases Survival Time for Advanced Pancreatic Cancer

May, 2010: An international study of world-leading breast cancer drug ABRAXANE ® (nanoparticle albumin-bound paclitaxel) has shown promising results for patients with advanced pancreatic cancer when used in combination with Gemcitabine.

ABRAXANE® Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer

March, 2010: An international lung cancer trial has shown positive results in those patients treated with the leading breast cancer drug ABRAXANE in combination with carboplatin.

PBS Change for Leading Breast Cancer Drug ABRAXANE®

June 7, 2010: Melbourne pharmaceutical company Specialised Therapeutics Australia (STA) wishes to announce a change in the Pharmaceutical Benefits Scheme (PBS) listing for its lead product ABRAXANE® (nanoparticle albumin-bound paclitaxel).

ABRAXANE® Granted Orphan Drug Status for Pancreatic Cancer by Therapeutic Goods Administration

February, 2010: A leading Australian breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been granted orphan drug status by the Therapeutic Goods Administration (TGA) for pancreatic cancer.

Abraxis Bioscience and Specialised Therapeutics Announce Approval to Market ABRAXANE® for Metastatic Breast Cancer in New Zealand

July, 2010: Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.